Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

VIR

Phase 1

VIR-5500

Cancer, metastatic-castration resistant prostate cancer

Q1 2025

11/7/24- Share initial clinical data in Q1 2025.

Data readout

KROS

Phase 1

KER-065

Obesity

Q1 2025

1/3/24- Trial initiated w/ initial data in Q1 2025.

Data readout

ANNX

Phase 1a

ANX1502

CAD (Cold Agglutinin Disease) / Autoimmune Indications

Q1 2025

12/20/23- Ph1 results from SAD & MAD study. Q3 '24- POC study transitioned to enhanced tablet formulation with data in Q1 2025.

Data readout

KTTA

Phase 1

PAS-004

Solid tumors [RAS, NF1 and RAF mutated]

Q1 2025

9/9/24- Completed long-term chronic toxicity studies. 9/26/24- Reported initial interim safety & PK data. 1/14/25- Interim data from Cohort 4 in Q1 2025. 2/5/25- SRC recommended trial escalate to next dose level.

Data readout

IGMS

Phase 1

Aplitabart (IGM-8444) (DR5 agonist) + FOLFIRI +/- bevacizumab

Second-line metastatic colorectal cancer

Q1 2025

8/3/23- Initial data w/ FOLFIRI single arm combo reported in 06/2023. 12/5/23- Prioritized trial. 5/8/24 Enrollment target exceeded for combo trial w/ FOLFIRI; top-line PFS results in Q1 2025. Single-arm trial met target enrollment.

Data Readout

ENLV

Phase 1/2

Allocetra (Immunotherapy)

Knee Osteoarthritis [End stage]

Q1 2025

Ph1 initiated. Q2 '24 Reports Interim Ph1/2 read out. Top-line data in Q1 2025.

Data Readout

GALT

Phase 2b/3

Belapectin (GR-MD-02)

Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH)

end of Q1 2025

NAVIGATE trial. 4/9/24- DSMB recommended trial continuation. 12/20/24- Topline data reported. 1/10/25- Topline data presented at 2025 MASH-TAG. 2/18/25- Reported add'l results. Full analysis ongoing with add'l data by end of Q1 2025.

Additional Data readout

ITCI

Phase 1

ITI-1020 (PDE-1 inhibitor)

Cancer

Early 2025

Q4 '23 Phase 1 SAD is ongoing. Readouts in early 2025

Data readout

JAZZ

Phase 2

Suvecaltamide (JZP-385)

PD (Parkinson's disease) tremor (PDT)

Q1 2025

Initiated Ph2 trial in Q3 2022 and enrolled first patient in Q4 2022. Trial is ongoing. Data in Q1 '25.

Data readout

LPTX

Phase 2

DKN-01 + pembrolizumab

Endometrial cancer

Q1 2025

Big Mover: Initial data in Q1 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20